Strength in Numbers: EU Cross-Country Drug Pricing Coalitions Join Forces
Concerns Emerge Over Insufficient Data To Support Decision-Making
Executive Summary
Two groups of smaller European countries have agreed to collaborate on tackling challenges relating to accessing expensive new medicines.
You may also be interested in...
Nordic Countries To Agree Closer Collaboration On Joint Price Negotiation And Procurement
Five Nordic countries are agreeing a common strategy for closer collaboration on access to hospital drugs.
European Countries Issue Alzheimer’s Biomarker Warning
Biogen/Eisai’s Alzheimer’s drug aducanumab could face difficulties with health technology appraisal institutes should it win approval in the EU.
European Countries Should Join Forces To Lower Prices of Zolgensma & Kaftrio
The Dutch HTA institute is calling for hefty discounts of 50% and 75% for Novartis’s gene therapy and Vertex’s cystic fibrosis product.